Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: Cohort study using data from the UK General Practice Research Database

British Journal of Clinical Pharmacology

Volumn 60, Issue 1, 2005, Pages 76-82

  Russmann, Stefan ^a,b   Kaye, James A ^a   Jick, Susan S ^a   Jick, Hershel ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Boston Collaborative Drug Surveillance Program   (United States)

Author keywords

Cholestasis; Flucloxacillin; GPRD; Liver disease; Oxytetracycline; Population based cohort study

Indexed keywords

DICLOXACILLIN; FLUCLOXACILLIN; OXYTETRACYCLINE;

ADULT; AGED; ARTICLE; AUSTRALIA; COHORT ANALYSIS; DATA BASE; DRUG LEGISLATION; FEMALE; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; STAPHYLOCOCCUS AUREUS; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHOLESTASIS; COHORT STUDIES; FAMILY PRACTICE; FEMALE; FLOXACILLIN; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS;

EID: 21744447422     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02370.x     Document Type: Article

References (27)

1. Australian Adverse Drug Reactions Advisory Committee (ADRAC) Flucloxacillin hepatitis. Australian Adverse Drug Reactions Bulletin 1990; 9: 2.
2. Bengtsson F, Floren CH, Hagerstrand I, Soderstrom C, Aberg T. Flucloxacillin-induced cholestatic liver damage. Scand J Infect Dis 1985; 17: 125-8.
3. Deboever G. Cholestatic jaundice due to derivatives of oxacillin. Am J Gastroenterol 1987; 82: 483.
4. Devereaux BM, Crawford DH, Purcell P, Powell LW, Roeser HP. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur J Clin Pharmacol 1995; 49: 81-5.
5. Eckstein RP, Dowsett JF, Lunzer MR. Flucloxacillin induced liver disease, histopathological findings at biopsy and autopsy. Pathology 1993; 25: 223-8.
6. Gotell P, Loof L. [Effects of floxacillin on the liver. 3 cases of floxacillin-induced cholestatic liver disease]. Lakartidningen 1987 84: 954-5.
7. Koek GH, Stricker BH, Blok AP, Schalm SW, Desmet VJ. Flucloxacillin- associated hepatic injury. Liver 1994; 14: 225-9.
8. Lobatto S, Dijkmans BA, Mattie H, Van Hooff JP. Flucloxacillin-associated liver damage. Neth J Med 1982; 25: 47-8.
9. Miros M, Kerlin P, Walker N, Harris O. Flucloxacillin induced delayed cholestatic hepatitis. Aust N Z J Med 1990; 20: 251-2
10. Turner IB, Eckstein RP, Riley JW, Lunzer MR. Prolonged hepatic cholestasis after flucloxacillin therapy. Med J Aust 1989; 151: 701-5.
11. Tauris P, Jorgensen NF, Petersen CM, Albertsen K. Prolonged severe cholestasis induced by oxacillin derivatives. A report on two cases. Acta Med Scand 1985; 217: 567-9.
12. Victorino RM, Maria VA, Correia AP, de Moura C. Floxacillin-induced cholestatic hepatitis with evidence of lymphocyte sensitization. Arch Intern Med 1987; 147: 987-9.
13. Fairley CK, McNeil JJ, Desmond P, et al. Risk factors for development of flucloxacillin associated jaundice. Br Med J 1993; 306: 233-5.
14. Davies MH, Harrison RF, Elias E, Hubscher SG. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 1994; 20: 112-6.
15. Jick H, Derby LE, Dean AD, Henry DA. Flucloxacillin and cholestatic hepatitis. Med J Aust 1994; 160: 525.
16. Derby LE, Jick H, Henry DA, Dean AD. Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993; 158: 596-600.
17. Australian Adverse Drug Reactions Advisory Committee (ADRAC). Fatal hepatic reactions to flucloxacillin. Australian Adverse Drug Reactions Bulletin 1994; 13: 10-1.
18. Roughead EE, Gilbert AL, Primrose JG. Improving drug use: a case study of events which led to changes in use of flucloxacillin in Australia. Soc Sci Med 1999; 48: 845-53.
19. UK Medicines Control Agency (MCA). Flucloxacillin-induced cholestatic jaundice. Current Problems Pharmacovigilance 1992; 35:2.
20. PRODIGY Guidance, http://www.prodigy.nhs.uk. Access date May 11, 2004.
21. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-9.
22. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992; 15: 154-61.
23. Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993; 158: 600-2.
24. Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy 1995; 15: 428-32.
25. Australian Adverse Drug Reactions Advisory Committee (ADRAC). A comparison of dicloxacillin with flucloxacillin. Australian Adverse Drug Reactions Bulletin 1999; 18: 7.
26. Roder BL, Frimodt-Moller N, Espersen F, Rasmussen SN. Dicloxacillin and flucloxacillin. pharmacokinetics, protein binding and serum bactericidal titers in healthy subjects after oral administration. Infection 1995; 23: 107-12.
27. Rodriguez-Solares A, Perez-Gutierrez F, Prosperi J, Milgram E, Martin A. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J Antimicrob Chemother 1993; 31(Suppl E): 103-9.